Ixekizumab + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis
Trial Timeline
Sep 14, 2015 โ Oct 30, 2018
NCT ID
NCT02584855About Ixekizumab + Placebo
Ixekizumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02584855. Target conditions include Psoriatic Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04285229 | Phase 3 | Completed |
| NCT03364309 | Phase 3 | Completed |
| NCT03129100 | Phase 3 | Completed |
| NCT02757352 | Phase 3 | Completed |
| NCT02696798 | Phase 3 | Completed |
| NCT02718898 | Phase 3 | Completed |
| NCT02584855 | Phase 3 | Completed |
| NCT02513550 | Phase 3 | Completed |
| NCT01107457 | Phase 2 | Completed |
Competing Products
20 competing products in Psoriatic Arthritis